AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- $0No open-market trades
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 8 added, 3 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- 2 awardsAwards on record
Key stats
Fundamentals Sep 30- Open
- $385.54
- 52-wk high
- $428.88
- High
- $391.33
- 52-wk low
- $161.90
- Low
- $378.50
- Prev close
- $386.87
- Mkt cap
- $46.46B
- P/E
- 36.6x
- Volume
- 1.31M
- Fwd P/E
- 24.3x
- Beta
- 0.74
- Div yield
- 0.91%
- P/S
- 0.3x
- P/B
- 2.3x
- Profit margin
- +0.9%
- Op margin
- +3.5%
- ROE
- +6.9%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about HUM filings
Are insiders buying or selling Humana Inc (HUM) stock?
Neither. Humana Inc (HUM) insiders filed no open-market purchases or sales in the 90 days to Oct 1, 2026, according to SEC Form 4 filings.
Which members of Congress have traded HUM recently?
None. No member of Congress disclosed a HUM trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this HUM smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position.
What funds are doing
Buys/Adds (3)
- SP
Slate Path Capital
$349.3M
added
- CI
Citadel
$153.8M
added
- SC
Steadfast Capital
$122.4M
bought
What Congress is doing
Sells (1)
How top traders are positioned
No tracked top-trader positions in HUM right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings landed in line with what analysts expected.
Earnings per share
$6.22 expected
Revenue
No comparable estimate
Company adjusted EPS
From the company's release
Compared on the analyst basis, which counts earnings differently from the company.
Reports Nov 4, 2026, in 34 days
Estimates as of Sep 30, 2026
EPS expected
-$1.16 to -$0.60
Revenue expected
17 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $32.65B | $32.52B | $39.65B | $40.87B |
| Cost of what it sold | $27.99B | $28.72B | $33.71B | $35.37B |
| Gross profit | $4.66B | $3.79B | $5.94B | $5.50B |
| What it spent | ||||
| Sales and admin | — | — | — | $3.98B |
| Other operating costs | $4.55B | $4.82B | $4.36B | $159.0M |
| Total operating expenses | $4.55B | $4.82B | $4.36B | $4.14B |
| What was left | ||||
| Operating profit | $108.0M | -$1.02B | $1.58B | $1.36B |
| Interest on debt | $168.0M | $146.0M | $193.0M | $197.0M |
| Profit before tax | $108.0M | -$1.02B | $1.58B | $952.0M |
| Tax | -$86.0M | -$249.0M | $395.0M | $238.0M |
| Net profit | $195.0M | -$796.0M | $1.19B | $693.0M |
| EBITDA | $480.0M | -$685.0M | $1.97B | $1.31B |
Technicals
Price structure
This stock is under pressure.
Trend
Under pressure
25 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace